IDEAYA Biosciences (IDYA)
(Delayed Data from NSDQ)
$39.50 USD
+0.33 (0.84%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $39.47 -0.03 (-0.08%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$39.50 USD
+0.33 (0.84%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $39.47 -0.03 (-0.08%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Zacks News
IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
IDEAYA Biosciences, Inc. (IDYA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Twist Bioscience (TWST) Stock Jumps 7.7%: Will It Continue to Soar?
by Zacks Equity Research
Twist Bioscience (TWST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of 12.20% and 33.64%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Akoya Biosciences (AKYA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Akoya (AKYA) delivered earnings and revenue surprises of -18.92% and 14.23%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of -2.33% and 0.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Amgen (AMGN) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Amgen (AMGN) delivered earnings and revenue surprises of 0.71% and 2.49%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
IDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of -51.61% and 70.76%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Gritstone bio Inc. (GRTS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of 16.28% and 2.13%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of -12.33% and 15.82%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
ProQR (PRQR) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
ProQR (PRQR) delivered earnings and revenue surprises of -15.38% and 69.50%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Cue Biopharma, Inc. (CUE) Stock Jumps 6.5%: Will It Continue to Soar?
by Zacks Equity Research
Cue Biopharma, Inc. (CUE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Earnings Preview: IDEAYA Biosciences, Inc. (IDYA) Q3 Earnings Expected to Decline
by Zacks Equity Research
IDEAYA Biosciences, Inc. (IDYA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IDEAYA Biosciences, Inc. (IDYA) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of -371.43% and -12.79%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of 0.00% and -27.31%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
IDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of 0.00% and -2.84%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
IDEAYA Biosciences (IDYA) Jumps: Stock Rises 8.2%
by Zacks Equity Research
IDEAYA Biosciences (IDYA) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
IDEAYA Biosciences, Inc. (IDYA) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of -126.34% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for IDEAYA Biosciences (IDYA) This Earnings Season?
by Zacks Equity Research
IDEAYA Biosciences (IDYA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Biotech Stock Roundup: REGN Begins Coronavirus Study, VRTX, BIIB Give Updates
by Zacks Equity Research
The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.
IDEAYA (IDYA) Looks Good: Stock Adds 10.2% in Session
by Zacks Equity Research
IDEAYA (IDYA) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
IDEAYA Biosciences Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
IDEAYA Biosciences has been struggling lately, but the selling pressure may be coming to an end soon.
IDEAYA Biosciences, Inc. (IDYA) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in IDEAYA Biosciences, Inc. (IDYA).